Product information and disease descriptionProduct descriptionProduct informationPharmacology
Mechanism of action
5 evidence topics · 7 sources
Gamma secretase inhibition of Notch signaling
Inhibition of all four Notch receptors
“BMS-986115 is a potent and selective inhibitor of gamma-secretase mediated Notch signalling and inhibits all 4 mammalian Notch receptors (Notch1 to 4) with low nanomolar median inhibitory concentrations (IC50s).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“AL101 (formerly BMS-906024) and AL102 (formerly BMS-986115) are structurally similar GSIs that are parenterally and orally administered, respectively, that inhibit activation of all four human Notch receptors” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Wnt/β-catenin and Notch pathway cross-talk in desmoid tumors
“Both sporadic DT and familial adenomatous polyposis (FAP)-associated DT are linked to constitutive activation of the Wnt signaling pathway with mutations in the β-catenin oncogene CTNNB1 or the tumor suppressor gene APC, respectively. Cross-talk between the Notch and Wnt pathways, as well as activation of the Notch pathway resulting from dysregulation of the Wnt pathway, suggest a possible therapeutic target for DT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Due to the role γ-secretase plays in Notch signaling through cleavage of the Notch intracellular domain (with subsequent translocation to the nucleus to activate gene transcription), γ-secretase inhibitors (GSIs) have emerged as a potential treatment for DT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Along with overexpression of β-catenin, desmoid tumors highly express Notch1, with cross-talk between these pathways putatively contributing to proliferation of desmoid tumors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Nonclinical studies have shown that γ-secretase inhibition prevents release of the Notch intracellular domain, which blocks Notch pathway signaling and cell growth.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Notch target gene expression in desmoid tumor tissue
“In DT, evidence for dysregulation of Notch signaling was observed in in vitro studies showing that DT tissues expressed higher levels of Notch1 and its downstream target HES1” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Subsequent studies analyzed the expression of Notch pathway components in DT tissues and cell strains, and confirmed increased expression of HES1 in DT versus dermal scar tissue” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote